The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Logna     but-2-enedioic acid; [(4R,5R)-9-chloro-2...

Synonyms: d-TA-3090, SureCN387182, AC1O5JZR, LS-40512, TA 3090, ...
This record was replaced with 57026.
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of CLENTIAZEM


High impact information on CLENTIAZEM

  • In paced hearts (250 beats/min), 0.5 microM TA-3090 had no effect on either peak systolic pressure development or contractility [2].
  • Like diltiazem, TA-3090 (10(-6)-10(-4] produced a dose-dependent inhibition of immunoreactive PTH release at 0.5 mM Ca2+ and raised the cytosolic Ca2+ concentration by 25-50% in fura-2-loaded parathyroid cells in the presence but not in the absence of extracellular Ca2+, suggesting that it activated rather than inhibited Ca2+ channels [6].
  • To investigate further possible mechanisms underlying these effects, we examined the effects of the more potent diltiazem analog TA-3090, which is a Ca2+ channel antagonist in vascular smooth muscle, on several aspects of the function of dispersed bovine parathyroid cells [6].
  • In contrast, diabetic dogs treated with TA-3090 had an elevated PGC [7].
  • Our findings support a role for TA-3090 directly on enterocyte absorption and/or intracellular lipid transport, and thus indicate the importance of intracellular calcium on these processes [8].

Chemical compound and disease context of CLENTIAZEM

  • We conclude that although treatment of diabetic dogs with either lisinopril or TA-3090 results in differential effects on PGC; each produces a similar decrement in proteinuria [7].
  • The enhanced hypotensive effect of TA-3090 was also observed in deoxycorticosterone acetate (DOCA)-salt hypertensive rats in which the minimum hypotensive dose of TA-3090 was 1 mg/kg p.o. In SHR, reflex tachycardia induced by TA-3090 was smaller than those induced by 1,4-DHPs, while diltiazem decreased the heart rate [9].
  • The hypotensive effect of a new 1,5-benzothiazepine derivative, TA-3090 ((+) (2S,3S)-3-acetoxy-8-chloro-5-(2-(dimethylamino)ethyl)-2, 3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4-(5H)-one maleate), was studied in various models of experimental hypertension [9].

Biological context of CLENTIAZEM

  • Thus, TA-3090 decreased arterial pressure through a fall in total peripheral resistance without major cardiac effects in both rats strains [10].
  • Intravenous administration of TA-3090 (0.025-0.2 mg/kg) produced increases in cardiac output and arterial, especially vertebral and coronary blood flow as well as in left ventricular dp/dtmax [11].

Anatomical context of CLENTIAZEM

  • In femoral (but not coronary) artery rings with endothelium, acetylcholine (10(-8) M) inhibited relaxations to TA 3090 [12].
  • The study indicates that both TA-3090 and nifedipine did not significantly affect L-type Ca2+ channels related to catecholamine release in the adrenal medulla under the present experimental conditions [13].
  • Suppression of water shift into intracellular space by TA-3090 (calcium entry blocker) measured with NMR [14].
  • These results indicate that TA-3090 has potent Ca2+-antagonistic and spasmolytic activities, and these actions are most selective for basilar artery [15].
  • Thus, TA-3090 could be demonstrated to possess potent and long-lasting vasodilating activity with selectivity for vertebral and coronary arteries, exerting however, weak negative inotropic effect [11].

Associations of CLENTIAZEM with other chemical compounds


Analytical, diagnostic and therapeutic context of CLENTIAZEM

  • In this study, TA-3090, a new calcium channel blocker with minimal effect on myocardial work load, was used to study the effect of calcium channel blockade on both myocardial substrate utilization and reperfusion recovery of ischemic hearts [2].
  • In vitro studies using jejunal organ culture to examine the effect of TA-3090 on intracellular lipid synthesis and secretion revealed that the addition of the drug to the medium resulted in significantly decreased TG synthesis and secretion [8].
  • Plasma level of radioactivity in rats reached plateau (6.04 micrograms equiv. of TA-3090 free base/ml) 1 h after oral administration [16].


  1. Pharmacology of TA-3090 (8-chloro diltiazem) related to its cerebrovascular protective properties. Bevan, J.A., Kaminow, L., Laher, I., Thompson, L.P. Circulation (1989) [Pubmed]
  2. Effects of TA-3090, a new calcium channel blocker, on myocardial substrate utilization in ischemic and nonischemic isolated working fatty acid-perfused rat hearts. Davies, N.J., McVeigh, J.J., Lopaschuk, G.D. Circ. Res. (1991) [Pubmed]
  3. Comparison of converting enzyme inhibitor and calcium channel blocker in hypertensive glomerular injury. Tolins, J.P., Raij, L. Hypertension (1990) [Pubmed]
  4. Effects of a new calcium channel blocker, TA 3090, on serum lipoprotein levels in mild to moderate essential hypertension. Sasaki, J., Ideishi, M., Saku, K., Arakawa, K., Tominaga, K., Saeki, Y., Otake, N., Kawasaki, K., Shirai, K., Sumida, I. Clinical therapeutics. (1990) [Pubmed]
  5. Sustained myocardial protection by clentiazem (TA-3090) after a 90-minute coronary occlusion and 72 hours of reperfusion in dogs with collateral flow. Rousseau, G., Provost, P., Latour, J.G. J. Cardiovasc. Pharmacol. (1993) [Pubmed]
  6. The diltiazem analog TA-3090 mimics the actions of high extracellular Ca2+ on parathyroid function in dispersed bovine parathyroid cells. Chen, C.J., Brown, E.M. J. Bone Miner. Res. (1990) [Pubmed]
  7. Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria. Brown, S.A., Walton, C.L., Crawford, P., Bakris, G.L. Kidney Int. (1993) [Pubmed]
  8. The effect of a new calcium channel blocker (TA-3090) on lipoprotein profile and intestinal lipid handling in rodents. Levy, E., Smith, L., Dumont, L., Garceau, D., Garofalo, C., Thibault, L., Seidman, E. Proc. Soc. Exp. Biol. Med. (1992) [Pubmed]
  9. Long-lasting hypotensive and antihypertensive effects of a new 1,5-benzothiazepine calcium antagonist in hypertensive rats and renal hypertensive dogs. Narita, H., Murata, S., Yabana, H., Kikkawa, K., Sugawara, Y., Akimoto, Y., Nagao, T. Arzneimittel-Forschung. (1988) [Pubmed]
  10. Immediate and prolonged hemodynamic effects of TA-3090 on spontaneously hypertensive (SHR) and normal Wistar-Kyoto (WKY) rats. Isshiki, T., Pegram, B.L., Frohlich, E.D. Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy. (1988) [Pubmed]
  11. Cardiovascular effects of a new 1,5-benzothiazepine calcium antagonist in anesthetized dogs. Murata, S., Kikkawa, K., Yabana, H., Nagao, T. Arzneimittel-Forschung. (1988) [Pubmed]
  12. Vascular actions of TA 3090, a novel analog of diltiazem: interaction with endothelium-dependent relaxation in canine femoral and coronary arteries. Rubanyi, G., Iqbal, A., Schwartz, A., Vanhoutte, P.M. J. Pharmacol. Exp. Ther. (1991) [Pubmed]
  13. Effects of clentiazem (TA-3090) and nifedipine on basal circulating catecholamine levels and on stimulation-evoked adrenal catecholamine secretion in anesthetized dogs. Gaspo, R., Lamarche, L., Yamaguchi, N., de Champlain, J., Garceau, D. Can. J. Physiol. Pharmacol. (1992) [Pubmed]
  14. Suppression of water shift into intracellular space by TA-3090 (calcium entry blocker) measured with NMR. Yamamoto, M., Haida, M., Taniguchi, R., Yazaki, K., Kurita, D., Fukuzaki, M., Shinohara, Y. Acta neurochirurgica. Supplementum. (1990) [Pubmed]
  15. Calcium antagonistic and spasmolytic activities of a new 1,5-benzothiazepine derivative in isolated canine and monkey arteries. Kikkawa, K., Murata, S., Nagao, T. Arzneimittel-Forschung. (1988) [Pubmed]
  16. Metabolic fate of the new Ca++-channel blocking agent (+)-(2S,3S)-3-acetoxy-8-chloro-(2-(dimethylamino)ethyl)-2,3-dihydro- 2-(4-methoxyphenyl)-2,5-benzothiazepin-4-(5H)-one maleate. Distribution, excretion and protein binding in rats and dogs. Nakamura, S., Ohashi, M., Suzuki, T., Sugawara, Y., Usuki, S., Takaiti, O. Arzneimittel-Forschung. (1989) [Pubmed]
WikiGenes - Universities